(Good) practice organizational models using real-world evidence for public funding of high prized therapies

The growing market entry of high-cost medicines threatens the financial sustainability of healthcare systems. Limited data available on the benefit of therapies at the time of approval poses a challenge for payers.  Outcome-based Managed-entry agreements (OBMEAs) present a reimbursement tool for payers to fund therapies and enable patient access - under conditions. The study aimed to design a generic organizational model for OBMEAs for highly-priced therapies, providing conditional funding while simultaneously generating publicly accessible data on the real-world evidence of treatment effects.

AIHTA Project Report No. 138